Today, combined radiochemotherapy is firmly established in clinical practice for a wide
spectrum of tumours. Randomized trials have shown that in many cases, this strategy may …

Over the last decade, BMC Cancer has continuously published important research from the
field of radiation oncology. Major developments in this field include the introduction of new …

Approximately 50% of all patients with cancer receive radiation therapy at some point during
the course of their treatment, and the majority of these patients are treated with curative …

The combination of chemotherapy and radiation has led to clinical breakthroughs in several
disease sites, and current work continues to define optimum combinations of proven …

Radiopharmaceutical therapy or targeted radionuclide therapy (TRT) is a well-established
class of cancer therapeutics that includes a growing number of FDA-approved drugs and a …

The rationale for delivering concomitant chemoradiation is not only to increase tumor cell kill
but also to achieve a synergistic effect of chemotherapy and radiation. Combination of …

Exposure of tumor cells to clinically relevant doses of ionizing radiation causes DNA
damage as well as mitochondria-dependent generation of reactive oxygen species. DNA …

The ideal radiation sensitizer would reach the tumor in adequate concentrations and act
selectively in the tumor compared with normal tissue. It would have predictable …

Substantial research efforts into predictive radiation oncology have so far produced very little
in terms of clinically applicable assays. This may change with the development of novel high …

Molecular targeted radionuclide therapy promises to expand the usefulness of radiation to
successfully treat widespread cancer. The unique properties of radioactive tags make it …